Silymarin's Advantage on Graft Effectiveness

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 130 participants.

Also called NCT06801886

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 130 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06801886
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Slovakia (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT06801886. Randomized; single masking; primary purpose prevention. Start 2020-01-07 (actual); primary completion 2025-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Silymarin's Advantage on Graft Effectiveness
Acronym
SAGE
Condition
Posttransplant Diabetes Mellitus
Condition
Acute Graft Rejection
Condition
Biopsy Proven Acute Rejection
Condition
Antibody Mediated Rejection of Kidney Transplant
Condition
Arterial Hypertension, Chronic Kidney Disease
Intervention (Drug)
Silymarine supplementation
Intervention (Other)
Placebo Supplementation
Lead sponsor
University Hospital, Martin (class: other)

Record details

Record id
cardio:ct-nct06801886
Content hash
34fe96a16251a7cefd54a634ef29e49c9b856eac2fd44dd7195bfb1d1173c39f